Parameter | Numbers | OR (95%CI) | P-values | |
---|---|---|---|---|
Total | Residual lesion (%) | |||
Age | ||||
≥ 50 | 254 | 42 (16.5%) | 1.355 (0.886–2.072) | 0.160 |
< 50 | 486 | 62 (12.8%) | ||
Menopause | ||||
Yes | 201 | 35 (17.4%) | 1.436 (0.922–2.238) | 0.108 |
No | 539 | 69 (12.8%) | ||
Smoking | ||||
Yes | 13 | 3 (23.1%) | 1.959 (0.503–6.872) | 0.409 |
No | 727 | 101 (13.9%) | ||
Diseases of the immune system | ||||
Yes | 64 | 9 (14.1%) | 1.001 (0.479–2.092) | 0.998 |
No | 676 | 95 (14.1%) | ||
Gravidity | ||||
≥ 3 | 506 | 67 (13.2%) | 0.813 (0.526–1.256) | 0.349 |
< 3 | 234 | 37 (15.8%) | ||
Parity | ||||
≥ 2 | 312 | 45 (14.4%) | 1.054 (0.694–1.602) | 0.805 |
< 2 | 428 | 59 (13.8%) | ||
Lesion range | ||||
≥ 3 | 409 | 69 (16.9%) | 1.716 (1.110–2.653) | 0.014* |
< 3 | 331 | 35 (10.6%) | ||
Cone margin status | ||||
Positive | 254 | 70 (27.6%) | 5.058 (3.244–7.885) | < 0.001* |
Negative | 486 | 34 (7%) | ||
Glandular involvement | ||||
Positive | 568 | 98 (17.3%) | 5.769 (2.483–13.404) | < 0.001* |
Negative | 172 | 6 (3.5%) | ||
HPV-16/18 infection | ||||
Positive | 408 | 79 (19.4%) | 2.949 (1.832–4.746) | < 0.001* |
Negative | 332 | 25 (7.5%) | ||
Multiple HR-HPV infection | ||||
Positive | 191 | 38 (19.9%) | 1.818 (1.172–2.818) | 0.007* |
Negative | 549 | 66 (12%) | ||
Lesion level | ||||
CIN II | 58 | 6 (10.3%) | 0.688 (0.288–1.644) | 0.397 |
CIN III | 682 | 98 (14.4%) |